Theseus Pharmaceuticals Income Statement

Financials in millions VND. Fiscal year is January - December.

Millions VND. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023
Period Ending	Jun '25 Jun 30, 2025	Dec '24 Dec 31, 2024	Jan '24 Jan 1, 2024
Revenue	328,281	583,807	627,201
Revenue Growth (YoY)	-47.66%	-6.92%	-
Cost of Revenue	160,200	413,019	498,076
Gross Profit	168,081	170,788	129,125
Selling, General & Admin	17,407	17,713	15,928
Operating Expenses	17,407	17,713	15,928
Operating Income	150,674	153,075	113,197
Interest Expense	-68,067	-68,067	-107,978
Interest & Investment Income	36,252	36,252	76,453
Earnings From Equity Investments	1,342	521.7	-5,120
Currency Exchange Gain (Loss)	0.2	0.2	-4.15
Other Non Operating Income (Expenses)	15,636	-123.27	17.44
EBT Excluding Unusual Items	135,838	121,659	76,565
Gain (Loss) on Sale of Investments	-4.23	-4.23	29.51
Gain (Loss) on Sale of Assets	612.78	612.78	-
Other Unusual Items	20,550	20,550	-
Pretax Income	156,996	142,817	76,594
Income Tax Expense	3,747	3,420	4,755
Earnings From Continuing Operations	153,249	139,397	71,839
Minority Interest in Earnings	-32,428	-31,780	-13,400
Net Income	120,821	107,616	58,439
Net Income to Common	120,821	107,616	58,439
Net Income Growth	106.75%	84.15%	-
Shares Outstanding (Basic)	10	10	10
Shares Outstanding (Diluted)	10	10	10
EPS (Basic)	12081.48	10761.64	5843.89
EPS (Diluted)	12081.48	10761.64	5843.89
EPS Growth	106.74%	84.15%	-
Free Cash Flow	96,747	589,234	-281,667
Free Cash Flow Per Share	9674.18	58923.36	-28166.70
Dividend Per Share	-	-	1500.000
Gross Margin	51.20%	29.25%	20.59%
Operating Margin	45.90%	26.22%	18.05%
Profit Margin	36.80%	18.43%	9.32%
Free Cash Flow Margin	29.47%	100.93%	-44.91%
EBITDA	199,111	193,668	171,578
EBITDA Margin	60.65%	33.17%	27.36%
D&A For EBITDA	48,436	40,593	58,381
EBIT	150,674	153,075	113,197
EBIT Margin	45.90%	26.22%	18.05%
Effective Tax Rate	2.39%	2.40%	6.21%
Revenue as Reported	328,281	583,807	627,201

Source: S&P Global Market Intelligence. Standard template. Financial Sources.